Introduction
Immunotherapy with immune checkpoint inhibitors (ICIs) has achieved a remarkable improvement in overall survival (OS) in different tumor histologies, albeit the majority of patients display intrinsic resistance (1) . The response to programmed cell death protein 1 (PD-1) blockade requires a preexisting and flourishing immune response and involves determinants of adaptive immunity, such as a high number of tumor DNA mutations or neoantigens, the interspersed distribution of infiltrating effector T cells, a high level of the expression of PD-L1, or an IFN-related gene signature (2, 3) . In contrast, resistant tumors lack signs of immunogenicity and are definable as "immune-desert" based on the absence of local T cell reactivity (4) . Resistant tumors are also endowed with the innate anti-PD-1 resistance signature (IPRES) (5) , which involves specific genetic programs, including wound healing, epithelial-mesenchymal transition (EMT), extracellular matrix remodeling, TGF-β signaling, hypoxia, macrophage chemotaxis, and angiogenesis. Most of these mirror the transcriptional profile of myeloid-derived suppressor cells (MDSCs), a population of immature myeloid cells (IMCs) pathologically associated with cancer and known for their potent inhibitory activity on antitumor T cell immunity (6) . In addition, MDSCs directly coordinate cancer cell plasticity, triggering the EMT phenotype (7, 8) and activating signaling pathways often associated with drug resistance, stroma remodeling, and angiogenesis (9, 10) . MDSCs distribute systemically in cancer patients, accumulating in the peripheral blood, lymph nodes (LNs), and distant organs, where they facilitate cancer dissemination by forming the so-called premetastatic niche (6) . A high frequency of MDSCs in the peripheral blood, mainly comprising monocytic and polymorphonuclear subsets (9, 11) , is associated with poor prognosis (6, 12) and represents a possible mechanism of resistance to immunotherapies (11, (13) (14) (15) (16) (17) .
MDSC generation is believed to stem from conditioning of the BM by soluble tumor factors, including granulocyte-macrophage CSF (GM-CSF), macrophage CSF (M-CSF), granulocyte CSF (G-CSF), and other proinflammatory cytokines (6) . A delivery of tumor factors could be facilitated by shuttling organelles (18) . Extracellular vesicles (EVs), nanoparticles abundantly secreted by
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Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma (9, 11) . In an attempt to mimic this phenotype in vitro, we opted to use tumor EVs to convert normal myeloid cells. EVs were purified by differential centrifugation of conditioned medium (CM) from melanoma cell lines and evaluated for their morphology and marker profiles (Supplemental Figure 1A ; supplemental material available online with this article; https:// doi.org/10.1172/JCI98060DS1). Here, we report that CD14 + monocytes, when exposed for 24 hours to melanoma EVs isolated from short-term (INT12, LM38) and long-term (Mel501, 624.38) cultured cell lines, show downregulated HLA-DR expression and cancer cells, are involved in the intercellular transfer of proteins, lipids, and genetic material, such as RNAs and microRNAs (miRs) (19) (20) (21) . Because of their ability to recirculate in body fluids, EVs represent an ideal candidate in the process of BM conditioning that leads to MDSC generation (22, 23) . In the present work, we identified a panel of circulating miRs associated with monocytic MDSC (M-MDSC) activity in melanoma patients, representing a potential tool to assess the role of these cells in resistance to ICIs.
Results
The monocyte-MDSC transition is mediated by melanoma EVs. We and others have previously defined cancer-associated human + cells, as shown by modulation of HLA-DRA, IL6, and CCL2 transcripts (top). EV-MDSCs generated with autologous plasma EVs f1 and f2 of melanoma patient inhibit T cell proliferation (percentages indicated, bottom). (I) Western blot of plasma EV fractions (f1, f2) of HD and patient. gMFI, geo mean fluorescence intensity; RE, relative expression. FC was by using as calibrator untreated monocytes. P < 0.001 (A, right; E); P < 0.01 (A, left); P < 0.05 (H, top), paired Student's t test. P < 0.05, Mann-Whitney U test (D). *P < 0.05, ***P < 0.001, unpaired Student's t test (C, F). Data are representative of 2 (E, H, I) and 3 (A, B) experiments. jci.org
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we could ascertain the induction of functional EV-MDSCs in an autologous setting, i.e., with EVs purified from CM of a patient's melanoma cell line, which we incubated with the patient's monocytes isolated from PBMCs; these EV-MDSCs were able to inhibit autologous T cell proliferation ( Figure 1E ). Parallel experiments have been performed in a murine setting with EVs released by the Ret melanoma cell line established from skin melanomas developed by RET transgenic mice (ret-EVs) (26) . ret-EVs converted BM IMCs into MDSCs in vitro, boosting NO, inducible NOS (iNOS), and arginase-I expression and immunosuppressive activity on T cell proliferation (Supplemental Figure 2, A-C Figure 2E) .
increase of IL-6 and CCL2 transcription and secretion together with suppressive properties on activated T cells ( Figure 1 , A and B, and Supplemental Figure 1 , B and C), a phenotype we have named EV-MDSCs. Monocyte conditioning strictly relies on the presence of vesicles, as EV-depleted melanoma CM loses the ability to downregulate HLA-DR expression (Supplemental Figure 1D) . CD14 + HLA-DR neg M-MDSCs accumulate in the peripheral blood of metastatic melanoma patients, as compared with healthy donors (HD) ( Figure 1C ) (11, 24) , and show spontaneous production of immunosuppressive and protumor factors, such as IL-6, CCL2, and TGF-β (10, 11, 25) , detected ex vivo as RNA and proteins (Supplemental Figure 1E) . Their suppressive potential is documented by the boost or decrease of T cell proliferation upon depletion or readdition of CD14 + cells from patients' peripheral blood mononuclear cells (PBMCs) (Supplemental Figure 1F) . Interestingly, CD14
+ cells from patients retain the potential to acquire EV-MDSC features, measured as HLA-DRA downregulation in the presence of melanoma EVs ( Figure 1D ). Furthermore, tant at 118,000 g), as indicated by transmission electron microscopy (TEM) and bead-calibrated flow cytometry (Supplemental Figure 3B) . Interestingly, f1 EVs from melanoma patients' plasma downregulated HLA-DRA at RNA levels in HD CD14 + monocytes upon in vitro coculture, suggesting the presence of EV-MDSC-converting vesicles potentially derived from tumor cells ( Figure 1G ). This effect was less frequent with f2 EVs from melanoma patients, which, in contrast, induced an increase of HLA-DRA expression in HD monocytes. The upregulation of HLA-DRA at the RNA level could be ascribed to monocyte activation, possibly due to the presence of stimulating EVs in f2 plasma fractions, likely originating from antigen-presenting cells (APCs), similarly to what we observed with f1 and f2 from plasma of HDs ( Figure 1G ). Reports have indeed shown that plasma exosomes can activate monocytes by inducing the upregulation of HLA-DR and CD86 expression in healthy and pathological conditions (27, 28) .
Similarly to normal monocytes, monocytes from melanoma patients downregulated their HLA-DRA expression upon coculture with autologous plasma f1 and f2 EVs, accentuating the potential relevance of this phenomenon in vivo. Of note, EV-MDSCs generated with autologous plasma f1 and f2 EVs displayed an increased suppressive effect on T cell proliferation with respect to unconditioned monocytes (Figure 1H) . The actual presence of melanoma EVs in patients' plasma could be confirmed by protein analysis, showing that, in contrast with HD, both f1 and f2 EVs of the patient expressed the gp100 melanoma marker, with a tendency to accumulate in f1. These data may contribute to explaining the downregulation of HLA-DRA in HD monocytes that we observed predominantly with f1 plasma EVs from melanoma patients, as shown in Figure 1G . An increase in f1 could also be assessed for the EV markers Rab5B, CD63, and CD49b/VLA-2 integrin, while both fractions showed similar levels of the LAMP-2 EV marker ( Figure 1I ).
Since tumor EVs can circulate in body fluids together with EVs originating from immune and other cells, we tested to determine whether plasma EVs from advanced melanoma patients could also promote the EV-MDSC phenotype in vitro. EV screening of unprocessed plasma by nanoparticle tracking analysis (NTA) showed that patients' samples contained EVs in increased numbers and mean sizes as compared with those from HDs. Notably, the size of EVs directly correlated with the frequency of circulating MDSCs in matched peripheral blood samples, suggesting a potential link to the disease ( Figure 1F and Supplemental Figure 3A) . To obtain vesicles for functional studies, we applied a 2-step centrifugation protocol aimed at enriching for larger (f1, obtained at 16,500 g) versus smaller EVs (f2, obtained with subsequent centrifugation of f1 superna- (29) (30) (31) . Genes involved in increased survival and antiapoptotic effects (e.g., BCL2 and CDKN2A) were enhanced, together with some molecular hallmarks of murine MDSCs, including S100A8 and MMP9 ( Table 1 ). Gene Ontology (GO) enrichment analysis indicated that most of the upregulated genes were involved in various immune cell functions, including inflammatory response, apoptosis signaling pathways, signal transduction regulation, and wound healing (Supplemental Table 2 ). Notably, the expression pattern of bona fide MDSC hallmark genes in the human setting is detectable in EV-MDSCs at the transcriptional level. We also identified key chemokines for protumor myeloid cell functions and hematopoietic stem cell maintenance, includ- The CIBERSORT assessment of transcriptome data (34) shows a significant enrichment of the M0 fraction of nonpolarized monocytes (Supplemental Figure 4) rather than M1 and M2 polarized macrophage fractions (35) . In silico analysis of EV-MDSCregulated genes also indicated a consistent overlap with an MDSC gene list described in colon tumor tissue data sets (36) . To confirm the overlapping features of our EV-MDSCs with myeloid cells from cancer patients, we compared the transcriptomic profile of EV-MDSCs with those of monocytes sorted from the blood of patients with different tumor types (37) (38) (39) and found a significant enrichment of the overexpressed genes ( Figure 2D ).
Monocyte skewing to EV-MDSCs also showed changes in miR expression. Via profiling, 98 miRs were identified as differentially expressed between monocytes and EV-MDSCs (FC |1.2|, FDR < 0.05); 34 were differentially expressed, with a FC of ≥|2|, including miRs, such as miR-146a, miR-125, and miR-155, described as being involved in the regulation of classical and alternative myeloid cell activation ( Figure 3A and Supplemental Table 3 ) (40-42). Integrative analysis of miRs and gene expres- sion profiling data revealed regulatory networks governing key myeloid cell functions, including the chemotaxis, adhesion, differentiation, and recruitment of phagocytes, macrophages, and APCs (Supplemental Figure 5) . miRs induce the EV-MDSC phenotype in CD14 + monocytes. Since EVs are known miR carriers (43-45), we hypothesized that EV-mediated miR cargo is involved in the process of in vitro EV-MDSC conversion. Profiling enabled us to identify 104 miRs detectable in both melanoma EVs and matched tumor cells (Supplemental Table 4 ). By crossing this set of miRs with those overexpressed in EV-MDSCs and associated with gene downregulation, we selected the top upregulated miRs -namely, miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, and miR99b -as MDSC-associated miRs for subsequent studies ( Figure  3A ; Supplemental Table 5 ). The evaluation of these miRs in plasma EV fractions f1 and f2 of melanoma patients showed that they were all detectable and that 5 out of 8 miRs (miR-146a, miR-146b, let-7e, miR-99b and miR-125b) were enriched in the f1 EV fraction, while the others appeared equally distributed ( Figure 3B ). Similarly, melanoma cell line-derived EVs showed comparable levels of MDSC-miRs in f1 and f2, compatible with the release of larger and smaller EVs by melanoma cells in vitro. Of note, the miR content associated with the induction of EV-MDSCs, as shown by HLA-DRA downregulation in HD monocytes (Supplemental Figure 6) . The contribution of MDSC-miRs in MDSC conversion was then explored with the help of corresponding mimics transfected into HD monocytes. Similarly to EV-MDSCs, miR-transfected monocytes displayed downregulation of HLA-DRA and the induction of IL6 and CCL2 expression ( Figure 3C ). In line with their MDSC nature, these cells also exerted suppressive activity on T cells, as suggested by the impairment of proliferation, CD25 expression, and IFN-γ and TNF-α secretion in T cell receptor-triggered (TCR-triggered) autologous T cells ( Figure 3D) . Conversely, the transfection of melanoma patient-derived monocytes with miR inhibitors led to their functional recovery ( Figure 3E ), indicating that MDSC-miRs play a role in sustaining myeloid cell-related protumor effects. The potential link of MDSC-miR expression and the accumulation of MDSCs in melanoma patients' peripheral blood was also supported by a significantly higher expression of 6 out of 8 MDSC-miRs in the patients' samples, which we observed upon comparing the levels of MDSC-miRs in CD14 + cells sorted from PBMCs of HD with those of metastatic stage IIIC-IV melanoma patients at treatment baseline (i.e., at ≥ 1 month apart from any systemic therapy) ( Figure 3F ).
We next assessed the contribution of direct MDSC-miR transfer from a tumor to monocytes via EVs with the aid of EVs derived from melanoma cells silenced for miR-146a, miR-100, miR-125b, and miR-155. miR-devoid EVs lost the ability to convert monocytes into EV-MDSCs in terms of HLA-DRA downmodulation, CCL2 and IL6 induction, and MDSC-miR upregulation ( Figure  4, A and B) . Similarly, the contemporaneous inhibition of these MDSC-miRs by adding miR inhibitors to melanoma EV-exposed monocytes from HD abrogated the acquisition of the EV-MDSC phenotype as well as suppressive activity on T cell activation and cytokine production (Figure 4 , C-E). Of note, the addition of miR inhibitors to a patient's monocytes conditioned with EVs deriving from the autologous melanoma cell line also restored T cell activity and cytokine release ( Figure 4F ).
Taken together, these results show that MDSC-miRs display an increased expression in monocytes of patients, circulate within EVs in patients' plasma, and condition myeloid cells via EV-mediated transfer. than were the high scores ( Figure 6B) . A comparable trend was observed when PFS was analyzed (Supplemental Figure 8) . Most importantly, when these data were divided by the type of therapy, the difference in OS between low and high scores was much more evident, with a P value of 0.003, for ICI-treated patients; no difference was detected for TKI-treated patients. Comparable data were observed for PFS; however, the curves for ICI patients were less divergent than were those for OS due to the known minor impact of ICIs on PFS (2). These data clearly indicate that our MDSCmiRs may represent predictive markers of the response to or the benefit of ICIs in advanced melanoma patients.
Discussion
In the present work, we discovered a set of miRs that associates with the phenotypic and functional features of M-MDSCs in melanoma patients. These miRs are detected in plasma as associated with EVs, in blood monocytes, and in tumor biopsies, as correlated with the frequency of altered myeloid cells. Most importantly, higher circulating levels of these miRs cluster with shorter PFS and OS in patients receiving ipilimumab and nivolumab, but not in those treated with BRAF/MEK inhibitors. These latter findings, if prospectively validated, pave the way for the development of what, to our knowledge, represents the first predictive peripheral blood biomarker of resistance to ICIs in cancer. The assessment of MDSC-miRs would make use of the concept of liquid biopsy (46) , which has traditionally focused on genetic tumor features (47), but surely could be implemented with information from the systemic environment, including host immunity (48) . The evidence that factors associated with myeloid-related immune suppression might influence disease outcome in melanoma patients is not unexpected, as higher MDSC frequency is a constant in poor disease prognosis, even during ICI administration (14-17). The true predictive role of the MDSC-miRs here identified might instead reflect specific functional properties that MDSCs could exhibit once immune responses are unleashed by the ICIs (29) . This hypothesis is in line with preclinical data showing that tumor resistance to PD-1 or CTLA4 blockade can be reverted by myeloid cell depletion (49, 50) .
Major evidence, albeit primarily in murine models, indicates a central role of miR-mediated posttranscriptional regulation in MDSC differentiation and function (40, 51) . Via in vitro studies on monocyte conditioning, we found that hallmarks of human MDSCs, i.e., downregulation of HLA-DR, secretion of IL-6, TGF-β, and CCL2, and inhibition of T cell proliferation and function (9, 10), can be reconstituted by in vitro cotransfection of the 8 MDSC-miRs; this finding held true even when the requirement was decreased to 4 miRs (miR-146a, miR-100, miR-125b, and miR-155) in some donors (data not shown). The chance of capturing such a complex regulatory scenario likely stems from the use of tumor EVs for MDSC generation. Indeed, EVs are known to carry distinct sets of miRs and to deliver them into target cells for the induction of specific functions, a key mechanism of intercellular crosstalk (52) . In the context of cancer, transformed cells exploit EV-mediated miR transfer to mold host tissues by triggering angiogenesis, EMT, invasion and metastasis, immune escape, and multidrug resistance (23, 43) . Here, we provide experimental proof that melanoma EVs are embedded with a set of miRs
MDSC-miRs are enriched in correlation with myeloid cell accrual.
The relevance of MDSC-miRs was next investigated ex vivo in human melanoma specimens. As expected, we detected high miR146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, and miR-99b levels in subcutaneous, visceral, and LN metastases from stage III-IV melanoma patients (n = 58) by qPCR, confirming the expression of these miRs by this tumor type (Supplemental Figure 7) . Interestingly, MDSC-miRs correlated with myeloid markers CD163, CD14, CD209, CD68, ITGAM (CD11b/Mac-1), and CD33 detected in the same samples, but not with T cell markers CD3, CD4, and CD8 or with tumor-related markers PMEL, TYR, MLANA, miR-21, and miR-211; the only exceptions were miR-155 and miR-100, which correlated with CD4 ( Figure 5A and Supplemental Table 6 ). Multivariate statistical analysis showed a significant correlation between the MDSC-miR cluster and the expression of all myeloid markers (P = 0.0062, r = 0.5491). Additionally, the correlation of CD14 and CD163 expression with the miR-146a, miR-100, miR-125b, and miR-155 clusters was also significant (P = 0.0455, r = 0.2088). The association of MDSC-miRs with infiltrating myeloid cells at the RNA level was confirmed by the correlation of miR-146a, miR-125b, and miR-146b with the number of CD163 + cells in tumor sections ( Figure 5B ). Indeed, in situ hybridization revealed that miR-146a, miR-100, miR-125b, and miR-155 expression was localized in both CD163 + and melanoma cells ( Figure 5C ). These data suggest that these miRs might be indicators of MDSC activity at the tumor site.
MDSC-miRs are enriched in the plasma of melanoma patients and cluster with resistance to immunotherapy.
To assess MDSCmiRs in the circulation, we measured their expression levels in plasma obtained from melanoma patients with advanced disease (stage IIIC unresectable and stage IV) (n = 20) and from a group of age-and sex-matched HD (n = 20). The analysis showed increased levels of all MDSC-miRs in the patients, with statistically significant differences shown for miR-146a, let-7e, miR-125a, and miR146b ( Figure 6A) . Notably, the expression levels of the studied miRs appeared more intercorrelated in patients than in HD (data not shown), further indicating an association with disease.
To test the potential for using MDSC-miRs as peripheral blood-based markers, we conducted a retrospective analysis in a set of plasma samples obtained from metastatic melanoma patients (n = 87) receiving either ICIs (ipilimumab or nivolumab) or targeted therapy (tyrosine-kinase inhibitors [TKIs] ; vemurafenib or the combination of dabrafenib and trametinib). Enrolled patients included 49 and 37 patients in the ICI and TKI groups, respectively (Supplemental Table 7 ). The expression levels of MDCS-miRs in the baseline samples were analyzed and correlated with OS and progression-free survival (PFS), both singly and jointly, in the latter case via a machine learning tool known as adaptive index modeling (AIM). By estimating the joint contribution of the 5 miRs showing an association with disease outcomes in univariable assessments (let-7e, miR-125a, miR-99b, miR-146b, and miR-125b), we were able to divide patients into 5 groups on the basis of an index score comprising the number of miRs showing increased expression, as detailed in Methods. Regarding OS, by pooling low scores (0-1; consisting of 0 or only 1 increased miR) versus high scores (>1; having 2 to 5 altered miRs), we observed that the low scores were associated with significantly better OS jci.org Volume 128 Number 12 December 2018 els holds promise as a potential biomarker to assess and monitor systemic immunosuppression in cancer patients, possibly predicting their chance of responding to ICIs.
Methods
Human studies. Peripheral blood samples from fasting patients and HD were processed within 2 hours for plasma collection and PBMC isolation and storage (11) . PBMCs from stage III-IV patients obtained before surgery or medical treatment were studied for MDSCs by immunophenotyping, and sorted CD14 + cells were assayed for cytokine, miR expression, and MDSC conversion and suppressive function. Plasma from stage IIIC-IV patients at baseline prior to any medical treatment was studied for circulating EVs and miRs. Metastatic tumor specimens obtained from stage IIIC-IV melanoma patients were snap-frozen and processed for RNA extraction and analyses. Mouse studies. C57BL/6 mice were purchased from Charles River Laboratories. In vivo and ex vivo interaction studies investigating the effects of ret melanoma EVs on myeloid cells involved the i.p. injection of 200 μg EVs, labeled with Cell Proliferation Dye eFluor 670 (Thermo Fisher Scientific) for interaction, or unlabeled EVs injected 3 times every 48 hours. Four days after the last injection, the animals were sacrificed to collect the BM and spleen cells for flow cytometry evaluation. CD11b Cell cultures. Melanoma cell lines were generated in our laboratory from human melanoma specimens (71) . The ret mouse melanoma cell line was established from the skin tumors of ret transgenic mice (26) . Mycoplasma contamination was tested periodically.
Isolation of EVs. According to a standardized protocol optimized for large-scale EV production, the supernatant of 10 9 human melanoma cells, cultured for 72 hours in RPMI 1640 medium containing 10% EV-depleted FCS (obtained by centrifuging FCS 2 hours at 118,000 g), 2 mM l-glutamine, and 200 U/ml penicillin/streptomycin, was centrifuged at 300 g for 10 minutes, 0.22 μm vacuum filtered (Millipore), and ultracentrifuged (Sorvall WX Ultra 100, Thermo Fisher Scientific) at 100,000 g for 2 hours at 4°C. Subsequently, collected EVs were suspended in PBS and washed by ultracentrifugation (1 hour, 118,000 g, 4°C). After protein quantification (Bradford Protein Assay, Bio-Rad), aliquots were frozen at -80°C until further use. Ret murine melanoma EVs were purified from 48 hours serum-free CM of ret cells by sequential centrifugation (300 g for 10 minutes, 4,000 g for 20 minutes), 0.22 μm vacuum filtering, and ultracentrifugation at 100,000 g for 4 hours at 4°C. Further processing was analogous to the process for EVs from human melanoma cell lines. Plasma samples were obtained from EDTA blood samples after centrifugation at 3000 g for 10 minutes, followed by plasma centrifugation at 3000 g for 10 minutes. For EV isolation, 500 μl plasma diluted 1:8 times with 0.1 μm-filtered PBS was centrifuged at 16,500 g for 10 minutes to obtain the fraction 1 EV pellet, and the supernatant was centrifuged at 118,000 g for 1.5 hours to sediment the fraction 2 EVs. The same protocol was also applied to isolate f1 and f2 human melanoma EVs from CM. NTA. The size distribution and concentration of EVs purified from CM of melanoma cells (5 μg diluted 1:10,000) and of EVs in unprocessed plasma samples (5 μl diluted 1:10,000) or cell-depleted CM ready to convert monocytes into bona fide MDSCs upon direct transfer. As this process is mimicked by ret-EVs injected in vivo into C57BL/6 mice (Supplemental Figure 2E) , it is reasonable to hypothesize that MDSC accumulation in melanoma patients might also involve in vivo myeloid conditioning by tumor EVs. The ability of these nanoparticles to distribute in body fluids (20) and reach the BM as well as other immunoregulatory sites could then account for the alteration of myelopoiesis, as depicted by our mouse studies as well as by previous preclinical data (18) .
An in vitro tumor-mediated conversion of differentiated monocytes to MDSC-resembling cells was already reported by others (53) . This process can be explained by the high plasticity of monocyte differentiation that cancer can arrest and shift toward immunoregulatory/suppressive mediators, as originally described for sepsis and cardiovascular diseases (54) . This evidence supports the recently introduced hypothesis that cancer-associated myeloid dysfunctions could stem not only from progenitor conditioning in the BM, but also from the peripheral reprogramming of circulating differentiated monocytes and neutrophils (55, 56) .
Most of the miRs here identified are involved in myeloid cell differentiation and polarization by participating in pathways often associated with cancer-related immunosuppression (57) (58) (59) . For instance, miR-146a, one of the most studied myeloid miRs (40) , is reported to serve as negative feedback in the TLR4-mediated activation of NF-κB-related genes (60) and to promote M2 polarization in both humans and mice (42) . miR-155, in addition to its key role in T cell responses (61) , is the top upregulated miR in GM-CSF-and IL6-induced MDSCs and is involved in STAT3 activation via SHIP-1 and PTEN targeting (62) . This miR has also been shown to facilitate tumor growth by promoting MDSC accrual, survival, and function through SOCS1 inhibition (63) (64) (65) (66) . Similarly, miR-125b and miR-125a have been implicated in monocyte differentiation toward immunosuppressive phenotypes (40, 42) via a pathway involving Lin28A (67), a key factor in hematopoietic stem cell growth and survival (68) . miR-125b is produced with miR-100 from a common primary polycistronic transcript; miR-99b, let-7e, and miR-125a are produced via a similar mechanism (69) , which explains their coordinated expression in tumor biopsies and in circulating monocytes from melanoma patients ( Figure 5A and Figure 3F ). The miR-99b/let-7e/miR-125a miR cluster was also shown to play a role in the mechanisms that stabilize STAT-3 activity in tolerogenic APC (70) . Specific insights into the pathways targeted by MDSC-miRs derive from matching their predicted gene panels with the transcriptional profile of EV-MSDCs, an analysis that provides key information about the vital processes of cancer-related myeloid dysfunctions involving chemotaxis, adhesion, and differentiation, with nodes including expected and previously unidentified patterns (Supplemental Figure 5) .
Overall, our study sheds light on the poorly defined patterns of human MDSC activity, providing strong evidence about the role of defined miRs in driving cancer-related myeloid cell reprogramming. The involvement of MDSC activation and expansion in limiting the clinical efficacy of ICIs is also strengthened by our results, pointing to the need for drugs for the correction of myeloid dysfunctions (51) to overcome immunotherapy resistance in melanoma patients. Finally, the evaluation of MDSC-miR plasma lev-jci.org
miRNA Plasma Kit (Macherey-Nagel) was used for RNA isolation. 250 μl of plasma were used. Before performing RNA extraction, EV samples were treated with RNAse A (10 μg/ml, Sigma-Aldrich) for 1 hour at 37°C. miR expression levels were evaluated using Thermo Fisher reagents; a preamplification step was included in this process.
To evaluate MDSC-miRs in the plasma of patients, RNA was reverse transcribed and preamplified with Megaplex RT and PreAmp Primers Human Pool A and tested in duplicate with TaqMan Array MicroRNA Cards (Thermo Fisher Scientific). To set up miRNA analysis by customized cards, the system conditions relative to spike-in use, retrotranscription, and preamplification conditions were defined in titration experiments and ath-miR-159a to control RNA extraction and U6 snRNA were used for quality control. All samples were tested in the same batch of cards. The cards were run on QuantStudio 7 Flex, and analysis was performed with QuantStudio 6 and 7 Flex software. Gene expression and miR microarray profiling. Gene expression profiles were generated using the HumanHT-12 v4 WGDASL BeadChip array (Illumina), and miR profiles were obtained using custom SurePrint Human miRNA Microarrays (Agilent). Raw gene expression data were log 2 transformed and normalized with robust spline normalization using the lumi package (73) . Probes with a detection P value of less than 0.01 in at least 1 sample were kept, and for each gene, the probe with the highest detection rate was selected. Raw miR data were background corrected with the normexp method and quantile normalized using the limma package (74) . Only probes with intensity higher than 10% of the 95th percentile of the negative controls in at least 1 sample were kept. The intensities of replicate probes were averaged, and the probes with the highest mean expression across samples were selected for each miR. Differential expression analysis was carried out with the limma package. P values were corrected for multiple testing using the Benjamini-Hochberg FDR. Genes and miRs with FDR of less than 0.05 and absolute FC of 1.2 or more were considered significant. All original microarray data were deposited in the NCBI's Gene Expression Omnibus database (GSE102011). Functional analyses were generated through the use of IPA (QIAGEN Inc., https://www. qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) and Gene Set Enrichment Analysis (GSEA) (75) . In silico evaluation of subpopulations was assessed with CIBERSORT (34) .
IHC and ISH. Melanoma sections were stained for CD163 after antigen retrieval performed by heating in a pressure cooker with citrate buffer at pH 6, 5 mM for 15 minutes and using the Dako REAL Detection System Alkaline Phosphatase/RED kit and red AP as a chromogen (Dako Agilent). Sections were scanned using the Aperio ScanScope XT systems (Aperio Technologies, Leica Microsystems), and signal quantifications were conducted by image analysis by MIAQuant as described previously (76) . ISH analysis for miR visualization was performed by hybridization with double-DIG-LNA probes and positive and negative controls (Exiqon), as previously described (77) . High-resolution Z stacks were acquired using Olympus BX63 equipped with a DP89 camera and cellSens software (Olympus).
Statistics. Data were analyzed using GraphPad Prism 5 and 7 software (GraphPad Software Inc.). Unless otherwise indicated, the results are presented as mean ± SD and in box and whiskers plots; the box boundaries represent the 25th and 75th percentiles, the middle line is the median value, and the whiskers represent the minimum and maximum values. The results were analyzed using 2-tailed unpaired or paired Student's t tests, Mann-Whitney U tests, and Pearson's and of melanoma cells (dilution 1:2) were determined using an LM10-HS NanoSight instrument and evaluated with NTA software (Malvern Instruments). Preparations were analyzed 5 times for 30 seconds.
TEM. Freshly isolated plasma EV preparations were fixed with 4% paraformaldehyde and deposited on Formvar carbon-coated nickel grids. Grids were doubly stained with uranyl acetate and lead citrate and examined by TEM (CM 10 Philips; FEI).
Western blot analysis. Proteins obtained from purified EVs and cells were separated on 4% to 12% Bis-Tris precast gels (Invitrogen), transferred to nitrocellulose membranes (Amersham), and incubated with Abs. Reactive proteins were visualized using HRP-conjugated secondary Abs (Amersham) and enhanced chemiluminescence (Amersham, SuperSignal). The list of Abs used is provided in Supplemental Table 8 .
Flow cytometry. To perform immunophenotyping studies, human and mouse cells were incubated with specific fluorochrome-conjugated Abs or isotype controls, provided in Supplemental Table 8 , washed, and analyzed. Flow cytometry of EVs from melanoma cells was performed using sulfate/aldehyde 5 μm latex beads (Thermo Fisher Scientific) (72) . A SmartFlare detection probe for miR-146a was used according to the manufacturer's instructions (Merck Millipore). Samples were evaluated using a FACSCalibur (BD Biosciences) and a Gallios or Cytoflex flow cytometer (Beckman Coulter) and FlowJo software (TreeStar Inc.). Morphology of plasma EV fractions was assessed by acquisition with the Gallios flow cytometer (Beckman Coulter) after calibration with 200, 500, and 1000 nm beads (Polysciences).
Monocyte studies. Monocytes (purity >95%) were purified from buffy coats of HD and from patients' PBMCs by sorting with anti- RNA extraction and qPCR analysis. RNA was extracted from monocytes, EV-MDSCs, melanoma cells, and melanoma specimens with the mirVana miRNA Isolation Kit (Ambion). qPCR analysis was performed according to the manufacturer's instructions using Thermo Fisher Scientific and Exiqon reagents to evaluate gene and miR expression levels, respectively. The list of assays is provided in Supplemental Table 8 . The endogenous controls used for normalization were GAPDH and ACTB for genes and U6 snRNA and SNORD48 for miRs. qPCR was carried out in triplicate and run on the ABI Prism 7900HT instrument, and analysis was performed using SDS software, version 2. Spearman's correlations, as specified. A P value of less than 0.05 was considered significant. Multivariate analysis, simple correlations, partial correlations, and canonical correlations of variables were calculated using SAS and R statistical software. Variables were also ranked in order to standardize values before calculating the abovementioned correlations. Plasma miRs were investigated as putative prognostic factors, and their association with OS was first examined with univariable Cox's proportional hazard models. Their joint association with OS was then investigated by means of a machine-learning algorithm known as AIM. This approach was used to obtain an index score based on the following steps: (a) forward selection of the miRs significantly associated with the clinical endpoints of interest, OS and PFS, in a proportional-hazard Cox's regression model; (b) definition of an optimal cutoff for each selected miR (based on Ct); and (c) construction of the index score, as an enumeration of miRs above the cutoff value. The index score built on data included 5 miRs; hence, we could split the patient cohort into 2 groups based on index score of 0-1 (0 or 1 miR with altered expression) or index score of 2-5 (2 or more miRs with altered expression). OS and PFS curves according to the levels of the selected score were finally estimated with the Kaplan-Meier method. Study approval. The study protocol (code INT39/11 and INT40/11) for human studies was approved by the IRB of Fondazione IRCCS Istituto Nazionale dei Tumori and the Independent Ethics Committee. All participants, including melanoma patients and blood donors, gave informed written consent. All animal studies were approved by Regional Board of the state Baden-Wuertemberg (Karlsruhe).
